Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas
- 14 August 2012
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (16), 4249-4256
- https://doi.org/10.1158/1078-0432.ccr-12-1327
Abstract
Pancreatic ductal adenocarcinoma (PDA) remains a devastating disease with nearly equal incidence and mortality rates. Over the past few decades, a litany of randomized clinical trials has failed to improve the outcome of this disease. More recently, the combination chemotherapy regimen FOLFIRINOX has shown improvement in overall survival over the single agent gemcitabine, and nab-paclitaxel (an albumin-coated formulation of paclitaxel) in combination with gemcitabine has shown promising results in phase II studies. Despite limited impact on patient care as of yet, the molecular and biologic understanding of PDA has advanced substantially. This includes understanding the genomic complexity of the disease, the potential importance of the tumor microenvironment, the metabolic adaptation of PDA cells to obtain nutrients in a hypoxic environment, and the role of pancreatic cancer stem cells. These fundamental discoveries are starting to be translated into clinical studies. In this overview, we discuss the implications of biologic understanding of PDA in clinical research and provide insights for future development of novel approaches and agents in this disease.Keywords
This publication has 49 references indexed in Scilit:
- Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial NeoplasiaGastroenterology, 2012
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal AdenocarcinomaCancer Cell, 2012
- EMT and Dissemination Precede Pancreatic Tumor FormationCell, 2012
- Distant metastasis occurs late during the genetic evolution of pancreatic cancerNature, 2010
- The patterns and dynamics of genomic instability in metastatic pancreatic cancerNature, 2010
- Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancerBritish Journal of Cancer, 2010
- Pancreatic CancerNew England Journal of Medicine, 2010
- Antidiabetic Therapies Affect Risk of Pancreatic CancerGastroenterology, 2009
- Chronic Pancreatitis Is Essential for Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes in Adult MiceCancer Cell, 2007
- Cancer genes and the pathways they controlNature Medicine, 2004